Blood

Published by: American Society of Hematology  

People

  1. Sadelain
    Sadelain
  2. Scheinberg
    Scheinberg
  3. Lesokhin
    Lesokhin
  4. Landgren
    Landgren
  5. Giralt
    Giralt
  6. Brentjens
    Brentjens
  7. Hassoun
    Hassoun
  8. Landau
    Landau
  9. Korde
    Korde
  10. Mailankody
    Mailankody

Groups

  1. Center for Hematologic Malignancies (604)
  2. Hematologic Malignancies Research (604)
  3. Department of Medicine (540)
  4. Hematologic Malignancies, Division of (519)
  5. GSK Faculty (454)
  6. Sloan Kettering Institute Faculty (371)
  7. Molecular Pharmacology and Chemistry Program Faculty (323)
  8. Tow Center for Developmental Oncology (TCDO) (243)
  9. Adult Leukemia (219)
  10. Sloan Kettering Institute Postdocs (193)
Search Within
  1. "Hematologic Malignancies Research"
Formats
  1. Meeting Abstract (522)
  2. Journal Article (82)
Groups
  1. Center for Hematologic Malignancies (604)
  2. Hematologic Malignancies Research (604)
  3. Department of Medicine (540)
  4. Hematologic Malignancies, Division of (519)
  5. GSK Faculty (454)
  6. Sloan Kettering Institute Faculty (371)

More Groups

People
  1. Michel Sadelain (130)
  2. David Scheinberg (118)
  3. Alexander Lesokhin (110)
  4. Carl Landgren (102)
  5. Sergio Giralt (86)
  6. Renier Brentjens (73)

More People

Years
  1. 2024 (1)
  2. 2023 (30)
  3. 2022 (37)
  4. 2021 (22)
  5. 2020 (31)
  6. 2019 (35)

More Years

Publishers
  1. American Society of Hematology (604)

Results (604)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Whole-genome sequencing reveals evidence of two biologically and clinically distinct entities: Progressive versus stable myeloma precursor disease
    Meeting Abstract

    Oben, B.; Froyen, G.; Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Abascal, F.; Leongamornlert, D. A.; Derkach, A.; Geerdens, E.; Diamond, B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Transcriptional control of HP1a by the RNA binding proteins RBMX/L1 maintain chromatin state in myeloid leukemia
    Meeting Abstract

    Nguyen, D. T. T.; Prieto, C.; Liu, Z.; Wheat, J.; Perez, A.; Gourkanti, S.; Chou, T.; Barin, E.; Chow, A.; Taggart, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma
    Meeting Abstract

    Madduri, D.; Berdeja, J. G.; Usmani, S. Z.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Stewart, A. K.; Hari, P.; Htut, M.; O'Donnell, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The genomic complexity of multiple myeloma precursor disease can be predicted using copy number signatures on targeted sequencing and SNP array data
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; Landgren, O.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and poor clinical outcome in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Evaluation of minimal residual disease (MRD) negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR Study
    Meeting Abstract

    Landgren, O.; Weisel, K.; Dachs, L. R.; Moreau, P.; Turgut, M.; Hajek, R.; Mollee, P.; Kim, J. S.; Zhang, J.; Go, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Lesokhin, A. M.; Levy, M. Y.; Dalovisio, A. P.; Bahlis, N. J.; Solh, M.; Sebag, M.; Jakubowiak, A.; Jethava, Y. S.; Costello, C. L.; Chu, M. P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Assessment of minimal residual disease in a phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma
    Meeting Abstract

    Landgren, O.; Alsina, M.; Biran, N.; Vesole, D. H.; Wallace, P. K.; Fang, B.; Arnold, G.; Kimball, A.; Siegel, D. S.
    Blood (2020)

    Fulltext@MSK | Save

    • Blood – authorized name for:

    Name ISSN / ISBN Publisher
    Blood 0006-4971 American Society of Hematology
    Blood 00064971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 00064971 Unknown
    Blood 0006-4971 American Society of Hematology
    Blood 15280020 American Society of Hematology
    Blood 0006-4971 W.B. Saunders Co.
    Blood 1528-0020 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 15280020 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 00064971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology and American Society of Clinical Oncology
    Blood 0006-4971 American Society of Hematology
    Blood 15280020 Unknown
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 W.B. Saunders Co.
    Blood 1528-0020 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 00064971 2023
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology and American Society of Clinical Oncology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 1528-0020 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology
    Blood 0006-4971 American Society of Hematology